Phase I/IIa Dose-escalation Clinical Study of VAC-3S
Last updated on July 2021Recruitment
- Recruitment Status
- Completed
- Estimated Enrollment
- 24
Summary
- Conditions
- HIV -1 Infection
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 55 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT01549119
- Collaborators
- Not Provided
- Investigators
- Study Director: Raphael Ho Tsong Fang, DVM, PHD InnaVirVax
Get Well Soon